Rostafuroxin

Drug Profile

Rostafuroxin

Alternative Names: PST 2238

Latest Information Update: 19 Jul 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sigma-tau SpA
  • Developer CVie Therapeutics; Rostaquo; sigma-tau SpA
  • Class Androstanes; Antihypertensives; Furans; Small molecules
  • Mechanism of Action Adenosine triphosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypertension

Most Recent Events

  • 18 Dec 2015 Phase-II clinical trials in Hypertension in Taiwan (PO) (CVT-CV-001)
  • 03 Aug 2015 Taiwan's Ministry of Health and Welfare approves an application to conduct a phase IIb study for Hypertension in Taiwan
  • 12 Jun 2013 CVie Therapeutics initiates enrolment in a phase IIb trial for Hypertension in Italy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top